| INTRODUC TI ON
Cervical cancer has been a global threat to women's health. More than two-thirds of cervical cancers are classified as squamous cell carcinoma, [1] [2] [3] which is currently decreasing owing to intensive cervical screening and vaccination against HPV. The remainder are predominantly adenocarcinoma, which is on the rise worldwide, requiring prompt and practical measures against this disease. Cervical clear cell carcinoma is an extremely rare subtype of adenocarcinoma. It is histologically characterized by clear cytoplasm of cancer cells, closely resembling the features of its ovarian counterpart. 4 Due to the small number of cases, epidemiological, clinical, and pathological features of cCCC have remained largely unknown. [5] [6] [7] [8] [9] Limited information thus far reported includes that patients with cCCC at an advanced stage had poor prognosis, 10 and that in utero exposure to the antimiscarriage drug DES and HPV infection might be implicated in its pathogenesis. [11] [12] [13] [14] There are virtually no resources available for cCCC research either, such as genetically engineered mouse models, PDCs, or patient-derived xenografts. These situations make it yet more difficult to undertake research on cCCC.
Organoid culture is an emerging technique that enables infinite expansion of murine and human normal stem cells. 15, 16 To date, it has been applied to various research fields, including infectious disease models, 17 developmental biology, 18 and epithelial regeneration.
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We also reported the establishment of murine organoid-based carcinogenesis models for intestine, 20 lung, 21 hepatobiliary tract, 22 and pancreas. 23 These organoid culture techniques have now become common for patient-derived samples from diverse types of cancer, which revealed that tumor-derived organoids basically retained the morphology and genetic aberrations of the original tumors. [24] [25] [26] Although its validity in gynecologic tumors has long remained elusive, 27 we recently established an efficient culture method optimized for ovarian and endometrial tumors, 28 by modification of an MBOC protocol that we initially developed for a murine carcinogenesis model ex vivo.
29.
In an effort to systematically collect various gynecologic tumors as PDC, we experienced a case of cCCC. Based on its scarcity, we dared to undertake its organoid culture using our new modified protocol, although we had never cultured primary cervical adenocarcinoma before. In this study, we successfully propagated and characterized tumor-derived organoids, establishing a novel cell line that basically retained the features of the original tumor. This PDC will likely provide mechanistic insights into cCCC and serve as a promising resource for preclinical studies. 
| MATERIAL S AND ME THODS

| Patient information
| Isolation of tumor cells and primary organoid culture
The biopsy samples were minced and dissociated into small clusters or single cells by digesting with 2 U/mL dispase II, 1 mg/mL colla- 
| Pathological analysis
Organoids obtained by depolymerization of Matrigel with Cell Recovery Solution (BD Biosciences) were resuspended in iPGell (GenoStaff, Tokyo, Japan). The iPGell-embedded organoids or resected tumors were fixed in 10%-15% buffered neutral formalin, dehydrated, and embedded in paraffin. The detailed methods are described in Data S1.
| Genomic DNA analysis
NucleoSpin Tissue (Takara, Shiga, Japan) and a QIAmp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) were used for extraction of genomic DNA from organoids and FFPE samples of tumor and normal tissues, respectively, and subjected to NGS analysis as previously described, 30 and aCGH analysis. The detailed methods are described in Data S1.
| Tumorigenicity assay
Immunodeficient nude mice BALB/cA nu/nu were purchased from CLEA Japan (Tokyo, Japan). Animal studies were carried out with the approval of the Chiba Cancer Center for Ethics in Animal
Experimentation. Tumor-derived organoids corresponding to 5 × 10 5 cells were resuspended in 100 μL advanced DMEM/F12 mixed with 100 μL Matrigel at a 1:1 ratio and inoculated into one side of the dorsal skin of nude mice. Tumor development was monitored for 3 months. 
| Cell proliferation and drug sensitivity assay
| Retention of histological features of CCC component, but not SC component, in biopsyderived organoids
While we were characterizing the biopsy-derived organoids, the pa- Figure 1B ). However, the minor fraction proved to be SC, another rare subtype of cervical adenocarcinoma ( Figure 2C ).
To verify that the biopsy-derived organoids indeed derived from the CCC component of the original tumor, we set out to undertake IHC analysis. We selected multiple markers widely used to distinguish between CCC and SC. 31 Specifically, HNF1-β, Napsin A, ARID1A, and p53 were evaluated. The CCC cells of the original tumor were positive for HNF-1β as predicted, but also positive for ARID1A and negative for Napsin A, unlike typical ovarian CCC.
Accumulation of p53 was evident in CCC, but its expression level varied within the CCC area ( Figure 2C ). These results suggest that this cCCC case might be only partially similar to typical ovarian CCC in terms of histological features. In contrast, SC cells of the original tumor showed strongly positive for p53 and ARID1A, but not for HNF-1β, or Napsin A, compatible with the typical phenotype of ovarian SC ( Figure 2C ). We also confirmed that both organoids and the original tumor had high expression of Ki-67, indicative of active proliferation ( Figure 2C ). Collectively, these observations suggested that the organoids were likely derived from the CCC component, but not from the SC component. 
| Retention of original CCC histological features in organoid-derived xenograft
To further verify the CCC origin of the biopsy-derived organoids, we inoculated the organoids at passage 3 ( Figure 3A ) into the bilateral dorsal skin of nude mice. Initially, it appeared that a palpable tumor developed only on the right side ( Figure 3B ). However, a tiny nodule on the left side was later found at the time of death ( Figure 3C ). The cut surface of the right tumor indicated that it had indeed a solid nature ( Figure 3D ). Microscopic analysis by H&E staining revealed that both the nodules contained papillary and solid fractions ( Figure 3E ). Precise histological evaluation showed that both nodules were predominantly composed of cancer cells with nuclear atypia and clear cytoplasm ( Figure 3F ), strongly resembling the histological properties of the organoids and the original CCC ( Figure 2C ).
Immunohistochemical analysis also indicated that protein expression profiles in both nodules were significantly similar, including positive findings in HNF1-β, p53, and Ki-67 ( Figure 3F ). Based on these findings, we concluded that the organoids were highly likely to consist of a pure cCCC population and retain the original features of the tumor.
The right s.c. tumor was recovered as cCCC organoids, which remained almost the same in morphology to those before inoculation ( Figure 3G ). To confirm the reproducibility of the xenograft development from organoids, we tried inoculation of organoids again at passage 7. However, no s.c. tumor developed, even after 3 months.
These observations suggest that the biopsy-derived CCC organoids might have only low tumorigenic potential, which was further lowered during culture by unknown mechanisms.
| Retention of original CCC genetic aberrations and heterogeneity in biopsyderived organoids
In many types of cancers, it has been reported that tumor-derived organoids basically retained the majority of somatic mutations, copy number variations, and intratumoral heterogeneity observed in the original tumors. [32] [33] [34] To verify this notion in this case, we compared were shared in common ( Figure 4A ). These was a nonsynonymous mutation in MLH1 and a synonymous mutation in TFE3. The VAF for TFE3 was 37% in organoids and 49% in the original CCC ( Figure 4A ).
Being a synonymous mutation, it is unlikely that the TFE3 muta- In contrast, the original SC harbored a large number of mutations.
However, no shared mutations with organoids or the CCC component were identified, unequivocally revealing their distinct natures ( Figure 4A) . Notably, the SC component harbored multiple nonsynonymous mutations in DNA repair-related genes, including PARP1, FANCD2, and PMS2 (Table S1 ). Hence, it is possible that defects in DNA repair underlie the observed mutator phenotype in the original SC.
Based on the NGS data, we also estimated genome-wide copy number changes in these samples. Although the signal to noise ratio of the data was relatively low, it seemed likely that the copy number gain in MET and the genome-wide copy number changes were shared by organoids and the original CCC, but not by the original SC ( Figure 4B ).
| Serous carcinoma-specific microdeletion and biallelic inactivation of TP53
It has been well established that TP53 is almost invariably mutated in ovarian high-grade SC. 35 Together with the observation that p53
was accumulated in the original SC, and to a lesser extent in the original CCC ( Figure 2C ), we assumed that the tumor would likely harbor a TP53 mutation. However, NGS analysis did not uncover point mutations in TP53. We then carefully examined the raw NGS data for the TP53 gene, and found a 3-bp in-frame deletion (c.754_756
del CTC) exclusively in SC ( Figure 4C ), which could result in p53 accumulation in tumors. 36 Interestingly, we found a heterozygous SNV but it was difficult to confirm 1 copy loss from the putative copy number inferred from the NGS data.
We then set out to accurately measure copy number alterations by aCGH analysis. The FFPE samples of CCC organoid-derived xenograft and the tumor's CCC and SC components were compared. The copy number alterations of the xenograft were similar to those of the original CCC, with further accumulation of alterations in xenograft ( Figure 5A ). Specifically, we found chromosomal gain at 8 and 22, and loss at 13, 18, and 21 in common. In sharp contrast, the genomic copy number of SC was significantly altered. As predicted, 1 copy loss of TP53, along with whole chromosome 17p, was observed in SC ( Figure 5A ).
| Clear cell carcinoma-specific overexpression of MET
Copy number gain of MET in CCC and xenograft, but not in SC, was also confirmed by aCGH ( Figure 5A Moreover, pAKT was not detected in either SC or CCC-related samples ( Figure 5B ). These results suggest that MET might exert its prooncogenic effects through noncanonical pathways in this CCC case.
| Drug sensitivity of cCCC organoid-derived spheroids for anticancer drugs
For high-throughput drug screening, Matrigel-based organoids might not be ideal, as time-consuming and complicated procedures are usually required. Practically, spheroids and adherent cells are more favored. In this regard, we previously confirmed that organoids from ovarian and endometrial tumors could generally be turned into spheroids, and used for drug-sensitivity assay. 28 In a similar manner, we dissociated cCCC organoids into single cells and split them into organoid and spheroid cultures. Cells readily aggregated and developed large spheroids, in a comparable way to organoids in Matrigel ( Figure 6A ).
We noted that organoids and spheroids proliferated comparably at least for 1 week from the beginning of the culture ( Figure 6B ). Based on these observations, we reasoned that spheroid-based drug sensitivity assay would mimic similar responses to organoids, if carried out within 7 days. We then treated cCCC organoids with anticancer drugs commonly used in clinic for gynecological cancer. The IC 50
values for paclitaxel and cisplatin were 20 nmol/L and 19 μmol/L, respectively ( Figure 6C ), which were comparable to IC 50 values of ovarian cancer organoids for paclitaxel (10-100 nmol/L) and cisplatin (10-100 μmol/L), respectively. 28 The IC 50 value for gemcitabine was 37 nmol/L, which was comparable to that of pancreatic cancer organoids (1-100 nmol/L). 37 Given that ovarian and pancreatic cancers are relatively sensitive to these agents, cCCC organoids would be likely sensitive to these drugs as well.
With amplification of the MET gene, we speculated that cCCC organoids would be sensitive to crizotinib, a clinically approved MET inhibitor, owing to a mechanism known as "oncogene addiction".
We included oHGSC that we recently established 28 as a negative 
| D ISCUSS I ON
In this study, we newly established a cell line from primary cCCC by organoid culture. Through detailed analyses of organoids and the original tumor, we confirmed that this PDC retained many features of the original cCCC, and can be subjected to drug screening in vitro as spheroids, and potentially in vivo as xenografts. We therefore designated the cell line as YMC7 for future distribution in the research community. To the best of our knowledge, this is the first successful ies with cCCC, we referred to studies in ovarian CCC, 40, 41 which is the second most common ovarian epithelial cancer in Japan. In this study, we also identified a 3-bp in-frame deletion and LOH in the TP53 gene in the SC component of the tumor. Accumulation of p53 was also observed, consistent with the same 3-bp deletion in ovarian SC. 36 These observations suggest that aberration of the TP53 gene might be implicated in the carcinogenesis of cervical SC as well.
Based on these findings, we now propose possible mechanisms un- Another possibility is that both components occurred from distinct lesions of normal cervical epithelia in a completely independent manner, which is known as a collision tumor, although it is relatively rare in gynecological tumors.
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In conclusion, we established a novel cell line of an extremely rare gynecological cancer. This cell line will not only contribute to elucidation of its pathogenesis, but also provide a preclinical model for drug discovery, accelerating both basic and translational research in gynecological cancer.
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